Helicobacter pylori Seropositivity in Patients with Interleukin-1 Polymorphisms Is Significantly Associated with...

Area of Science:

• Cardiology
• Infectious Diseases
• Genetics

Background:

• Helicobacter pylori infection and interleukin-1 gene polymorphisms are known risk factors for gastric cancer.
• The study investigated the prevalence of H. pylori seropositivity and interleukin-1 polymorphisms in patients with acute coronary syndromes.

Purpose of the Study:

• To determine the association between H. pylori seropositivity, interleukin-1 polymorphisms, and acute coronary syndromes.
• To evaluate the impact of these factors on high sensitivity C-reactive protein levels and myocardial infarction risk.

Main Methods:

• Recruited patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
• Analyzed interleukin-1 beta-511 and interleukin-1 receptor antagonist polymorphisms using PCR.
• Measured immunoglobulin G antibodies against H. pylori and high sensitivity C-reactive protein.

Main Results:

• The combined presence of H. pylori seropositivity and interleukin-1 polymorphisms was significantly higher in STEMI patients (42.7%) compared to NSTE-ACS patients (25.7%).
• H. pylori-seropositive individuals with interleukin-1 polymorphisms exhibited elevated high sensitivity C-reactive protein levels.
• Multivariate analysis indicated that the co-occurrence of H. pylori seropositivity and interleukin-1 polymorphisms was a significant predictor of STEMI (OR, 2.32).

Conclusions:

• The simultaneous presence of H. pylori seropositivity and interleukin-1 polymorphisms is associated with increased high sensitivity C-reactive protein levels.
• This combination significantly increases the risk of ST-segment elevation myocardial infarction, suggesting a potential role in cardiovascular disease pathogenesis.